flucytosine has been researched along with Benign Neoplasms in 40 studies
Flucytosine: A fluorinated cytosine analog that is used as an antifungal agent.
flucytosine : An organofluorine compound that is cytosine that is substituted at position 5 by a fluorine. A prodrug for the antifungal 5-fluorouracil, it is used for the treatment of systemic fungal infections.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Systemic candidiasis is a disease of increasing incidence and proportions, which appears to be associated with the advances in modern medicine." | 2.38 | Systemic candidiasis. ( Ray, TL, 1989) |
| "We found that cancer cells stably transduced with yCD::UPRT gene by retrovirus infection released exosomes acting similarly like yCD::UPRT-MSC exosomes." | 1.62 | Intracellular prodrug gene therapy for cancer mediated by tumor cell suicide gene exosomes. ( Altaner, C; Altanerova, U; Babelova, A; Benejova, K; Jakubechova, J; Priscakova, P; Repiska, V; Smolkova, B, 2021) |
| " In addition, all MSCs were engineered to stably express luciferase gene making them suitable for quantitative imaging and dose-response relationship studies in animals." | 1.42 | Genetically engineered theranostic mesenchymal stem cells for the evaluation of the anticancer efficacy of enzyme/prodrug systems. ( Hatefi, A; Nouri, FS; Wang, X, 2015) |
| "In subcutaneous MDA-MB-435 human breast cancer xenograft models, RRV-mediated yCD and TK suicide gene therapy significantly suppressed tumor growth after prodrug administration." | 1.36 | Highly efficient gene transfer to solid tumors in vivo by tumor-selective replicating retrovirus vectors. ( Lu, YC; Luo, YP; Tai, CK; Wang, YW, 2010) |
| "These cancers are characterized by length alterations in ubiquitous simple sequence repeats, a phenotype called microsatellite instability." | 1.35 | Abrogation of microsatellite-instable tumors using a highly selective suicide gene/prodrug combination. ( de Wind, N; Ferrás, C; Oude Vrielink, JA; te Riele, H; Tsaalbi-Shtylik, A; Verspuy, JW, 2009) |
| "One important feature of human solid tumors is the presence of a hypoxic microenvironment." | 1.33 | Development of a hypoxia-inducible cytosine deaminase expression vector for gene-directed prodrug cancer therapy. ( Deen, DF; Hu, L; Kong, EL; Lamborn, KR; Rehemtulla, A; Ruan, H; Wang, D, 2005) |
| "In contrast, CD-UPRT-expressing tumors had increased CD gene activity with a threefold higher intratumoral accumulation of 5FU and significant generation of F-nucs." | 1.32 | The use of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies. ( Chen, M; Chenevert, TL; Dornfeld, KJ; Gelovani, JT; Hamstra, DA; Lawrence, TS; Lee, KC; Moffat, BA; Rehemtulla, A; Ross, BD; Schepkin, VD; Tychewicz, JM, 2004) |
| "longum accumulated in hypoxic solid tumors." | 1.31 | Cloned cytosine deaminase gene expression of Bifidobacterium longum and application to enzyme/pro-drug therapy of hypoxic solid tumors. ( Amano, J; Fujimori, M; Kano, Y; Nakamura, T; Sasaki, T; Taniguchi, S; Yazawa, K, 2002) |
| "Patients with AIDS were younger and predominantly male; they had a shorter duration of prior illness, higher initial serum cryptococcal antigen titers, and lower initial cerebrospinal fluid white blood cell counts than those with neoplastic disease." | 1.28 | Cryptococcal meningitis: outcome in patients with AIDS and patients with neoplastic disease. ( Armstrong, D; Blevins, A; Cirrincione, C; White, M, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (10.00) | 18.7374 |
| 1990's | 5 (12.50) | 18.2507 |
| 2000's | 20 (50.00) | 29.6817 |
| 2010's | 9 (22.50) | 24.3611 |
| 2020's | 2 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ho, YK | 1 |
| Loke, KM | 1 |
| Woo, JY | 1 |
| Lee, YL | 1 |
| Too, HP | 1 |
| Altanerova, U | 1 |
| Jakubechova, J | 1 |
| Benejova, K | 1 |
| Priscakova, P | 1 |
| Repiska, V | 1 |
| Babelova, A | 1 |
| Smolkova, B | 1 |
| Altaner, C | 3 |
| Sun, CH | 1 |
| Berg, K | 1 |
| Hirschberg, H | 1 |
| Harguindey, A | 1 |
| Roy, S | 1 |
| Harris, AW | 1 |
| Fairbanks, BD | 1 |
| Goodwin, AP | 1 |
| Bowman, CN | 1 |
| Cha, JN | 1 |
| Nouri, FS | 1 |
| Wang, X | 1 |
| Hatefi, A | 1 |
| Li, JJ | 1 |
| Chang, SF | 1 |
| Liau, II | 1 |
| Chan, PC | 1 |
| Liu, RS | 1 |
| Yen, SH | 1 |
| Wang, HE | 1 |
| Chang, CA | 1 |
| Ferrás, C | 1 |
| Oude Vrielink, JA | 1 |
| Verspuy, JW | 1 |
| te Riele, H | 1 |
| Tsaalbi-Shtylik, A | 1 |
| de Wind, N | 1 |
| Fuchita, M | 1 |
| Ardiani, A | 1 |
| Zhao, L | 1 |
| Serve, K | 1 |
| Stoddard, BL | 1 |
| Black, ME | 1 |
| Lu, YC | 1 |
| Luo, YP | 1 |
| Wang, YW | 1 |
| Tai, CK | 1 |
| Zhang, J | 1 |
| Wei, F | 1 |
| Wang, H | 1 |
| Li, H | 1 |
| Qiu, W | 1 |
| Ren, P | 1 |
| Chen, X | 1 |
| Huang, Q | 1 |
| Pfüller, R | 1 |
| Gräser, Y | 1 |
| Erhard, M | 1 |
| Groenewald, M | 1 |
| Yu, ST | 1 |
| Li, C | 1 |
| Lü, MH | 1 |
| Liang, GP | 1 |
| Li, N | 1 |
| Tang, XD | 1 |
| Wu, YY | 1 |
| Shi, CM | 1 |
| Chen, L | 1 |
| Li, CZ | 1 |
| Cao, YL | 1 |
| Fang, DC | 1 |
| Yang, SM | 1 |
| Yata, VK | 1 |
| Gopinath, P | 1 |
| Ghosh, SS | 1 |
| Nakamura, T | 1 |
| Sasaki, T | 1 |
| Fujimori, M | 1 |
| Yazawa, K | 2 |
| Kano, Y | 1 |
| Amano, J | 1 |
| Taniguchi, S | 1 |
| Akbulut, H | 1 |
| Zhang, L | 1 |
| Tang, Y | 1 |
| Deisseroth, A | 2 |
| Nemunaitis, J | 2 |
| Cunningham, C | 2 |
| Senzer, N | 1 |
| Kuhn, J | 1 |
| Cramm, J | 1 |
| Litz, C | 1 |
| Cavagnolo, R | 1 |
| Cahill, A | 1 |
| Clairmont, C | 1 |
| Sznol, M | 1 |
| Kuriyama, S | 1 |
| Tsujinoue, H | 1 |
| Yoshiji, H | 1 |
| Ozçelik, B | 1 |
| Citak, S | 1 |
| Cesur, S | 1 |
| Abbasoğlu, U | 1 |
| Içli, F | 1 |
| Hamstra, DA | 1 |
| Lee, KC | 1 |
| Tychewicz, JM | 1 |
| Schepkin, VD | 1 |
| Moffat, BA | 1 |
| Chen, M | 1 |
| Dornfeld, KJ | 1 |
| Lawrence, TS | 2 |
| Chenevert, TL | 1 |
| Ross, BD | 1 |
| Gelovani, JT | 1 |
| Rehemtulla, A | 2 |
| Wang, D | 1 |
| Ruan, H | 1 |
| Hu, L | 1 |
| Lamborn, KR | 1 |
| Kong, EL | 1 |
| Deen, DF | 1 |
| Tirandaz, H | 1 |
| Salehi-Najafabadi, A | 1 |
| Eslamifar, A | 1 |
| Liu, Y | 1 |
| Koziol, J | 1 |
| Borgstrom, P | 1 |
| Kucerova, L | 1 |
| Altanerova, V | 1 |
| Matuskova, M | 1 |
| Tyciakova, S | 1 |
| Royo, JL | 1 |
| Becker, PD | 1 |
| Camacho, EM | 1 |
| Cebolla, A | 1 |
| Link, C | 1 |
| Santero, E | 1 |
| Guzmán, CA | 1 |
| Gal-Mor, O | 1 |
| Finlay, BB | 1 |
| Kostiala, AA | 1 |
| Kostiala, I | 1 |
| Hay, RJ | 1 |
| Mackenzie, DW | 1 |
| Campbell, CK | 1 |
| Philpot, CM | 1 |
| Pizzo, PA | 1 |
| Harris, JD | 1 |
| Gutierrez, AA | 1 |
| Hurst, HC | 1 |
| Sikora, K | 1 |
| Lemoine, NR | 1 |
| Walsh, TJ | 1 |
| Lyman, CA | 1 |
| Judde, JG | 1 |
| Spangler, G | 1 |
| Magrath, I | 1 |
| Bhatia, K | 1 |
| Offner, F | 1 |
| Cordonnier, C | 1 |
| Ljungman, P | 1 |
| Prentice, HG | 1 |
| Engelhard, D | 1 |
| De Bacquer, D | 1 |
| Meunier, F | 1 |
| De Pauw, B | 1 |
| Lambin, P | 1 |
| Nuyts, S | 1 |
| Landuyt, W | 1 |
| Theys, J | 1 |
| De Bruijn, E | 1 |
| Anné, J | 1 |
| Van Mellaert, L | 1 |
| Fowler, J | 1 |
| Erbs, P | 1 |
| Regulier, E | 1 |
| Kintz, J | 1 |
| Leroy, P | 1 |
| Poitevin, Y | 1 |
| Exinger, F | 1 |
| Jund, R | 1 |
| Mehtali, M | 1 |
| Fisher, WE | 1 |
| Brunicardi, FC | 1 |
| White, M | 1 |
| Cirrincione, C | 1 |
| Blevins, A | 1 |
| Armstrong, D | 1 |
| Ray, TL | 1 |
6 reviews available for flucytosine and Benign Neoplasms
| Article | Year |
|---|---|
Emerging implications of nonmammalian cytosine deaminases on cancer therapeutics.
Topics: Animals; Cell Death; Cytosine Deaminase; Enzyme Stability; Flucytosine; Humans; Mammals; Neoplasms | 2012 |
Prodrug cancer gene therapy.
Topics: Animals; Antineoplastic Agents; Cytochrome P-450 Enzyme System; Cytosine Deaminase; Enzymes; Flucyto | 2008 |
New antifungal compounds and strategies for treatment of invasive fungal infections in patients with neoplastic diseases.
Topics: Amphotericin B; Antifungal Agents; Azoles; Flucytosine; Humans; Immunocompromised Host; Mycoses; Neo | 1995 |
The potential therapeutic gain of radiation-associated gene therapy with the suicide gene cytosine deaminase.
Topics: Animals; Antimetabolites; Cytosine Deaminase; Dose-Response Relationship, Drug; Flucytosine; Fluorou | 2000 |
Current progress in suicide gene therapy for cancer.
Topics: Animals; Antiviral Agents; Arabinonucleosides; Aziridines; Clinical Trials as Topic; Cytosine Deamin | 2002 |
Systemic candidiasis.
Topics: Amphotericin B; Candidiasis; Flucytosine; Humans; Immune Tolerance; Ketoconazole; Neoplasms; Opportu | 1989 |
2 trials available for flucytosine and Benign Neoplasms
| Article | Year |
|---|---|
Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients.
Topics: Aged; Aged, 80 and over; Cytosine Deaminase; Escherichia coli; Female; Flucytosine; Fluorouracil; Ge | 2003 |
A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-
Topics: Acyltransferases; Antimetabolites; Antimetabolites, Antineoplastic; Combined Modality Therapy; Cytos | 2001 |
32 other studies available for flucytosine and Benign Neoplasms
| Article | Year |
|---|---|
Cryopreservation does not change the performance and characteristics of allogenic mesenchymal stem cells highly over-expressing a cytoplasmic therapeutic transgene for cancer treatment.
Topics: Cell Line, Tumor; Cell Proliferation; Cryopreservation; Flucytosine; Humans; Mesenchymal Stem Cells; | 2022 |
Intracellular prodrug gene therapy for cancer mediated by tumor cell suicide gene exosomes.
Topics: Animals; Antineoplastic Agents; Cell Engineering; Cell Line, Tumor; Culture Media, Conditioned; Cyto | 2021 |
Photochemical Internalization Enhanced Nonviral Suicide Gene Therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cytosine Deaminase; Flucytosine; Fluorou | 2019 |
Click Nucleic Acid Mediated Loading of Prodrug Activating Enzymes in PEG-PLGA Nanoparticles for Combination Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cytosine Deaminase; DNA; Doxorubic | 2019 |
Genetically engineered theranostic mesenchymal stem cells for the evaluation of the anticancer efficacy of enzyme/prodrug systems.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cytosine Deaminase; Female; Flucyto | 2015 |
Targeted antitumor prodrug therapy using CNGRC-yCD fusion protein in combination with 5-fluorocytosine.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytosine Deaminase; Drug Delivery Systems; Flucytosine; Hum | 2016 |
Abrogation of microsatellite-instable tumors using a highly selective suicide gene/prodrug combination.
Topics: Animals; Antimetabolites; Cell Line; Cell Line, Tumor; Cytosine Deaminase; DNA Mismatch Repair; Fluc | 2009 |
Bacterial cytosine deaminase mutants created by molecular engineering show improved 5-fluorocytosine-mediated cell killing in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Combined Modality Therapy; Cytosine Deaminase; | 2009 |
Highly efficient gene transfer to solid tumors in vivo by tumor-selective replicating retrovirus vectors.
Topics: Animals; Antimetabolites; Antiviral Agents; Breast Neoplasms; Cell Line; Cytosine Deaminase; Female; | 2010 |
A novel oncolytic adenovirus expressing Escherichia coli cytosine deaminase exhibits potent antitumor effect on human solid tumors.
Topics: Adenoviridae; Adenoviridae Infections; Adenovirus E1A Proteins; Animals; Antimetabolites; Blotting, | 2010 |
A novel flucytosine-resistant yeast species, Candida pseudoaaseri, causes disease in a cancer patient.
Topics: Antifungal Agents; Candida; Candidemia; Cluster Analysis; DNA, Fungal; DNA, Ribosomal; DNA, Ribosoma | 2011 |
Noninvasive and real-time monitoring of the therapeutic response of tumors in vivo with an optimized hTERT promoter.
Topics: Animals; Cell Line, Tumor; Computer Systems; Cytosine Deaminase; Drug Monitoring; Flucytosine; Genes | 2012 |
Cloned cytosine deaminase gene expression of Bifidobacterium longum and application to enzyme/pro-drug therapy of hypoxic solid tumors.
Topics: Antimetabolites, Antineoplastic; Bifidobacterium; Blotting, Western; Cloning, Molecular; Cytosine De | 2002 |
Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon.
Topics: Adenoviridae; Adenovirus E1A Proteins; Animals; Breast Neoplasms; Cell Death; Colonic Neoplasms; Cyt | 2003 |
Immune response to suicide gene therapy.
Topics: Animals; Biotransformation; Bystander Effect; Enzymes; Flucytosine; Ganciclovir; Genes, Transgenic, | 2004 |
In vitro susceptibility of Candida species isolated from cancer patients to some antifungal agents.
Topics: Amphotericin B; Antifungal Agents; Candida; Disease Susceptibility; Fluconazole; Flucytosine; Humans | 2004 |
The use of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies.
Topics: Animals; Antineoplastic Agents; Artificial Gene Fusion; Brain; Cytosine Deaminase; Diffusion Magneti | 2004 |
Development of a hypoxia-inducible cytosine deaminase expression vector for gene-directed prodrug cancer therapy.
Topics: Blotting, Western; Cell Hypoxia; Cell Line, Tumor; Cytosine Deaminase; Enhancer Elements, Genetic; E | 2005 |
Advances in radiosensitization.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Cetuxima | 2004 |
Cytosine deaminase producing Clostridium may be used in detection of tumors.
Topics: Bacterial Proteins; Clostridium; Cytosine Deaminase; Flucytosine; Fluorouracil; Humans; Neoplasms | 2006 |
Methods for delivery of adenoviral vectors to tumor vasculature.
Topics: Adenoviridae; Animals; BALB 3T3 Cells; Flucytosine; Fluorescent Antibody Technique; Gene Transfer Te | 2007 |
Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy.
Topics: Adipose Tissue; Animals; Antineoplastic Agents; Cell Line, Tumor; Cytosine Deaminase; Female; Flucyt | 2007 |
In vivo gene regulation in Salmonella spp. by a salicylate-dependent control circuit.
Topics: 3-Phosphoshikimate 1-Carboxyvinyltransferase; Animals; Aspirin; Bacterial Proteins; beta-Galactosida | 2007 |
Pathogens on aspirin: promising research and therapeutic applications.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bacterial Proteins; Flucytosine; Fluorour | 2007 |
Susceptibility of fungi in mouthrinse specimens from patients with haematological malignancies.
Topics: Antifungal Agents; Candida; Candida albicans; Candidiasis, Oral; Drug Resistance, Microbial; Flucyto | 1984 |
Cryptococcosis in the United Kingdom and the Irish Republic: an analysis of 69 cases.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Amphotericin B; Antigens, Fungal; Child; Collagen | 1980 |
Infectious complications in the child with cancer. II. Management of specific infectious organisms.
Topics: Amphotericin B; Bacterial Infections; Child; Flucytosine; Humans; Infections; Mycoses; Neoplasms; Pr | 1981 |
Gene therapy for cancer using tumour-specific prodrug activation.
Topics: Base Sequence; Biotransformation; Breast Neoplasms; Cytosine Deaminase; DNA Primers; Female; Flucyto | 1994 |
Use of Epstein-Barr virus nuclear antigen-1 in targeted therapy of EBV-associated neoplasia.
Topics: Antigens, Viral; Base Sequence; Cell Survival; Cytosine Deaminase; DNA-Binding Proteins; Epstein-Bar | 1996 |
Impact of previous aspergillosis on the outcome of bone marrow transplantation.
Topics: Amphotericin B; Anemia, Aplastic; Antifungal Agents; Aspergillosis; Bone Marrow Transplantation; Flu | 1998 |
In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene.
Topics: Adenoviridae; Animals; Artificial Gene Fusion; Cytosine Deaminase; Flucytosine; Gene Transfer Techni | 2000 |
Cryptococcal meningitis: outcome in patients with AIDS and patients with neoplastic disease.
Topics: Acquired Immunodeficiency Syndrome; Adult; Amphotericin B; Antifungal Agents; Drug Therapy, Combinat | 1992 |